Why we measure it

Prostate cancer is the most commonly diagnosed cancer in males and a leading cause of cancer death. The majority of deaths, however, occur in men whose cancer was either detected too late for curative treatment or not detected at all. The critical insight from the largest prostate cancer screening trial — the European Randomised Study of Screening for Prostate Cancer (ERSPC), which enrolled 182,000 men across seven European countries — is that PSA-based screening reduces prostate cancer mortality. The 16-year ERSPC data found a 21% reduction in prostate cancer mortality in the screened group, and a 27% reduction among those who actually attended screening. The USPSTF, in its 2018 recommendation update, reversed its prior position and recommended that clinicians offer PSA screening to men aged 55–69 after individual discussion — acknowledging the mortality benefit alongside the known risks of overdiagnosis and overtreatment of indolent cancers. For the Blueprint Bloodwork protocol, the rationale is specific: annual PSA testing beginning at 40 establishes a personal baseline before age-related BPH confounds the signal, allows tracking of PSA velocity (the rate of rise over time, which is independently predictive of cancer beyond the absolute level), and catches meaningful elevation early enough that further evaluation and treatment options remain broad. A man who has five years of annual PSA readings in the same range before seeing a rise has a fundamentally more interpretable result than one presenting with a first-ever PSA of 4.2 ng/mL at 58.

Why every 12 months

Prostate cancer, in most cases, grows slowly — PSA tends to rise over years rather than months, which is exactly why annual measurement is appropriate rather than more frequent testing. Annual draws provide the time resolution to calculate PSA velocity meaningfully: a rise of more than 0.75 ng/mL per year in men with PSA above 4.0 ng/mL, or more than 0.4 ng/mL per year in men with PSA below 4.0 ng/mL, has been shown in prospective studies to independently predict prostate cancer and, specifically, to predict fatal prostate cancer decades before diagnosis. This velocity signal — which requires serial annual measurements to compute — is a key reason why the protocol begins testing at 40 rather than 50 or 55.

What movement means

The historically used clinical threshold of 4.0 ng/mL to trigger biopsy has been substantially revised by the research literature. A landmark study by Thompson et al., published in the New England Journal of Medicine (2004), found prostate cancer in 15% of men with PSA below 4.0 ng/mL who were biopsied — and high-grade cancer (Gleason score ≥ 7) in 2.3% of men with PSA below 1.0 ng/mL. Cancer exists across the full PSA range. What the absolute PSA level does predict is cancer risk: risk increases continuously with PSA, with cancer found in approximately 10% of men with PSA 2.0–4.0 ng/mL, 25% of men with PSA 4.0–10.0 ng/mL, and more than 50% of men with PSA above 10.0 ng/mL. The ranges below describe relative risk categories based on this evidence — not diagnostic thresholds. The absolute PSA level is one input; PSA velocity, free:total PSA ratio, age, and clinical context together determine the appropriate next step.

In the protocol